HUE047521T2 - Vírusrészecskék stabilizálása - Google Patents
Vírusrészecskék stabilizálásaInfo
- Publication number
- HUE047521T2 HUE047521T2 HUE15158279A HUE15158279A HUE047521T2 HU E047521 T2 HUE047521 T2 HU E047521T2 HU E15158279 A HUE15158279 A HU E15158279A HU E15158279 A HUE15158279 A HU E15158279A HU E047521 T2 HUE047521 T2 HU E047521T2
- Authority
- HU
- Hungary
- Prior art keywords
- stabilisation
- viral particles
- viral
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005520.0A GB201005520D0 (en) | 2010-03-31 | 2010-03-31 | Stabilisation of viral particles |
| EP10250706 | 2010-03-31 | ||
| GBGB1005497.1A GB201005497D0 (en) | 2010-03-31 | 2010-03-31 | Method for stabilising viruses |
| GBGB1005521.8A GB201005521D0 (en) | 2010-03-31 | 2010-03-31 | Stabilised liquid formulations of virus particles |
| GBGB1014962.3A GB201014962D0 (en) | 2010-09-08 | 2010-09-08 | Mehtod for stabilising viruses |
| GBGB1017648.5A GB201017648D0 (en) | 2010-10-19 | 2010-10-19 | Liquid preparation containing stabilised viruses |
| GBGB1017647.7A GB201017647D0 (en) | 2010-10-19 | 2010-10-19 | Method for stabilising viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE047521T2 true HUE047521T2 (hu) | 2020-04-28 |
Family
ID=43903999
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15158279A HUE047521T2 (hu) | 2010-03-31 | 2011-03-31 | Vírusrészecskék stabilizálása |
| HUE11714373A HUE026885T2 (en) | 2010-03-31 | 2011-03-31 | Stabilize virus fragments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11714373A HUE026885T2 (en) | 2010-03-31 | 2011-03-31 | Stabilize virus fragments |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10206960B2 (enExample) |
| EP (2) | EP2552465B1 (enExample) |
| JP (1) | JP5960120B2 (enExample) |
| CN (1) | CN102892424B (enExample) |
| CA (1) | CA2795013C (enExample) |
| DK (2) | DK2898890T3 (enExample) |
| ES (2) | ES2543795T3 (enExample) |
| GB (1) | GB2499479A (enExample) |
| HU (2) | HUE047521T2 (enExample) |
| IL (1) | IL221858A (enExample) |
| WO (1) | WO2011121306A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206960B2 (en) | 2010-03-31 | 2019-02-19 | Stabilitech Biopharma Ltd | Stabilisation of viral particles |
| AU2011234264B2 (en) * | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| HUE042330T2 (hu) | 2010-03-31 | 2019-06-28 | Stabilitech Biopharma Ltd | Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| CN105579059B (zh) * | 2013-09-03 | 2020-07-31 | 佐治亚科技研究公司 | 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针 |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| KR20190104051A (ko) | 2017-01-06 | 2019-09-05 | 스타빌리테크 바이오파마 리미티드 | 바이러스 |
| GB2562241B (en) * | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| AR113996A1 (es) | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
| CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| AR119105A1 (es) * | 2019-06-07 | 2021-11-24 | Intervet Int Bv | Célula mutante bloqueada mdbk irf3 / irf7 y su uso para producción de vacunas |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| JP7712284B2 (ja) | 2020-03-12 | 2025-07-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスの安定性を改善する組成物 |
| WO2021215952A1 (ru) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Способ получения частиц бактериофагов семейства levivirus |
| AR127944A1 (es) | 2021-12-23 | 2024-03-13 | Intervet Int Bv | Vacunas líquidas estabilizadas de virus vivos |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927208A (en) | 1973-05-14 | 1975-12-16 | Rit Rech Ind Therapeut | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them |
| US4631189A (en) | 1980-03-10 | 1986-12-23 | Da Vinci Laboratories, a division of FoodScience Corporation | N,N-dimethylglycine and use in immune response |
| JPS6013718A (ja) | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ワクチン |
| JPS60193925A (ja) | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| JPS61189228A (ja) | 1985-02-19 | 1986-08-22 | Nippon Sekijiyuujishiya | 血液凝固第８因子製剤の製法 |
| US4950596A (en) | 1985-03-04 | 1990-08-21 | The Dow Chemical Company | Stabilization of intracellular enzymes |
| JPS6238173A (ja) | 1985-08-13 | 1987-02-19 | 三菱レイヨン株式会社 | 抗血液凝固剤 |
| US5169758A (en) | 1986-05-02 | 1992-12-08 | Boehringer Mannheim Gmbh | Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it |
| US4816568A (en) | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
| NZ221306A (en) | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| US4980277A (en) | 1987-10-16 | 1990-12-25 | Cultor Ltd. | Cryoprotectant solution and method |
| WO1989011297A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| GB8826429D0 (en) | 1988-11-11 | 1988-12-14 | Univ Leeds Ind Service Ltd | Enzyme stabilisation systems |
| EP0487632B1 (en) | 1989-08-15 | 1998-03-04 | Massachusetts Institute Of Technology | Stabilized vaccine compositions |
| CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
| WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| RU2099418C1 (ru) | 1991-11-21 | 1997-12-20 | Лонца Аг | Фрагмент днк, обеспечивающий использование бетаина, рекомбинантная плазмидная днк с фрагментом днк, обеспечивающим использование бетаина, штамм бактерий rhizobium/agrobacterium, предназначенный для стабильного хранения плазмиды с фрагментом днк, способ получения штамма бактерий |
| ZA936095B (en) | 1992-08-21 | 1994-03-14 | Univ Melbourne | Cytokine applications. |
| FR2698879B1 (fr) | 1992-12-09 | 1995-01-13 | Rhone Poulenc Biochimie | gellules modifiées au niveau du catabolisme de la bétaïne, préparation et utilisations, notamment pour la production de métabolites ou d'enzymes. |
| GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US5965438A (en) | 1995-06-07 | 1999-10-12 | Phyton, Inc. | Cryopreservation of plant cells |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| GB9521806D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Preservation methods |
| FR2746109B1 (fr) | 1996-03-12 | 1998-04-17 | Rhone Poulenc Rorer Sa | Milieu pour la conservation de materiel biologique |
| US20070179096A1 (en) | 1996-04-24 | 2007-08-02 | Novo Nordisk A/S | Pharmaceutical Formulation |
| US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
| AU707186B2 (en) | 1997-07-01 | 1999-07-01 | Transgene S.A. | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy |
| CA2312233A1 (en) | 1997-11-26 | 1999-06-03 | Universal Preservation Technologies, Inc. | Preservation of sensitive biological samples by vitrification |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| WO2000029024A1 (en) | 1998-11-16 | 2000-05-25 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| AUPQ347199A0 (en) | 1999-10-15 | 1999-11-11 | Csl Limited | Novel polypeptide fragments |
| JP2003535119A (ja) | 2000-06-08 | 2003-11-25 | パウダージェクト ワクチンズ，インコーポレーテッド | 粉末組成物 |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US20040110267A1 (en) | 2000-12-15 | 2004-06-10 | Stratagene | Room temperature stable competent cells |
| AU2002302814A1 (en) | 2001-06-08 | 2002-12-23 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| US7101693B2 (en) | 2001-09-07 | 2006-09-05 | Brigham Young University | Plasticized hydrophilic glasses for improved stabilization of biological agents |
| JP4936618B2 (ja) | 2001-09-21 | 2012-05-23 | 株式会社ノエビア | 微細エマルション組成物 |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| ATE441666T1 (de) | 2001-12-28 | 2009-09-15 | Kyowa Hakko Kirin Co Ltd | Antikírper gegen den fibroblastenwachstumsfaktor 23 |
| EP3210624A1 (en) | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| JP2003261591A (ja) | 2002-03-08 | 2003-09-19 | Koji Hayade | 凍結乾燥安定剤 |
| EP1539244A1 (en) | 2002-06-27 | 2005-06-15 | Novo Nordisk A/S | Use of dimethyl sulfone as isotonicity agent |
| CA2491805A1 (en) | 2002-07-10 | 2004-01-22 | Transgene S.A. | Modified adenoviral fiber with ablated binding to cellular receptors |
| WO2004035818A1 (en) | 2002-10-21 | 2004-04-29 | Biotage Ab | Use of osmolytes to heat stabilise luciferase and/or apyrase |
| AU2003297833A1 (en) | 2002-12-10 | 2004-06-30 | Schering-Plough Ltd. | Canine rankl and methods for preparing and using the same |
| PL1633391T3 (pl) | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilizowane farmaceutycznie kompozycje peptydowe |
| EP2292642A1 (en) | 2003-06-10 | 2011-03-09 | Opal Therapeutics Pty Ltd | Immunomodulating compositions, uses therefor and processes for their production |
| US20060247167A1 (en) | 2003-09-01 | 2006-11-02 | Novo Nordisk A/S | Stable formulations of peptides |
| US7642077B2 (en) | 2003-12-08 | 2010-01-05 | Genencor International, Inc. | Biocomposite comprising co-precipitate of enzyme, silicate and polyamine |
| EP1711619A4 (en) | 2003-12-30 | 2007-04-11 | Virumar Pituach Tarkivin Ltd | INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US20060058238A1 (en) | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
| WO2006039336A2 (en) | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| US8173148B2 (en) * | 2004-11-10 | 2012-05-08 | Tolmar Therapeutics, Inc. | Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid |
| CA2595380A1 (en) | 2005-01-28 | 2006-08-03 | Wyeth | Stabilized liquid polypeptide formulations |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| TWI398272B (zh) | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| JP5020935B2 (ja) | 2005-04-08 | 2012-09-05 | アルゴス セラピューティクス，インコーポレイティド | 樹状細胞組成物および方法 |
| SI1954308T1 (sl) * | 2005-09-16 | 2011-12-30 | Merial Ltd | Stabilizatorji za liofilizirana cepiva |
| RU2008117396A (ru) | 2005-10-04 | 2009-11-10 | Альк-Абелло А/С (Dk) | Твердая вакцинная композиция |
| AU2006315026B2 (en) | 2005-11-21 | 2012-11-22 | Sanofi Pasteur Limited | Stabilizing formulations for recombinant viruses |
| RU2424247C2 (ru) | 2005-11-30 | 2011-07-20 | Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. | Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка |
| CA2631714C (en) | 2005-12-02 | 2014-09-16 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| CN101495136A (zh) | 2006-02-15 | 2009-07-29 | 英克隆系统公司 | 抗体配制品 |
| US8021659B2 (en) | 2006-04-28 | 2011-09-20 | Naidu Lp | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
| ES2286951B1 (es) | 2006-05-26 | 2008-10-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A | Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas. |
| US20090053197A1 (en) | 2006-06-14 | 2009-02-26 | Ramaekers Joseph C | Transfer Factor Compositions and Methods |
| CA2668417A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| AU2008231072B2 (en) | 2007-03-22 | 2013-08-01 | The Regents Of The University Of Colorado | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| EP2150537A4 (en) | 2007-06-01 | 2010-09-22 | Acologix Inc | STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE |
| WO2009006097A1 (en) | 2007-06-29 | 2009-01-08 | Johnson & Johnson Regenerative Therapeutics, Llc | Liquid protein formulations comprising gdf-5 for use at elevated temperatures |
| CN101835479A (zh) | 2007-07-25 | 2010-09-15 | 佰欧益有限公司 | 多系祖细胞分化为软骨细胞 |
| US20090123436A1 (en) | 2007-11-08 | 2009-05-14 | Surmodics, Inc. | Cryopreservative compositions and methods |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| US20110212127A1 (en) | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| GB2479069B (en) | 2008-09-24 | 2012-07-25 | Stabilitech Ltd | Method for preserving polypeptides using a sugar and polyethyleneimine |
| BRPI0915696B8 (pt) | 2008-11-07 | 2021-05-25 | Serum Institute Of India Ltd | composição de vacina de rotavírus liofilizada e método de preparar a referida composição |
| WO2010132508A2 (en) * | 2009-05-11 | 2010-11-18 | Biomatrica, Inc. | Compositions and methods for biological sample storage |
| CN101670104A (zh) | 2009-09-24 | 2010-03-17 | 浙江大学 | 一种含人参皂甙的油佐剂及其制备方法 |
| US20130171128A1 (en) | 2010-03-02 | 2013-07-04 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| AU2011234264B2 (en) * | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| US10206960B2 (en) | 2010-03-31 | 2019-02-19 | Stabilitech Biopharma Ltd | Stabilisation of viral particles |
| HUE042330T2 (hu) | 2010-03-31 | 2019-06-28 | Stabilitech Biopharma Ltd | Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
-
2011
- 2011-03-31 US US13/637,817 patent/US10206960B2/en active Active
- 2011-03-31 CA CA2795013A patent/CA2795013C/en active Active
- 2011-03-31 HU HUE15158279A patent/HUE047521T2/hu unknown
- 2011-03-31 EP EP11714373.5A patent/EP2552465B1/en active Active
- 2011-03-31 DK DK15158279T patent/DK2898890T3/da active
- 2011-03-31 ES ES11714373.5T patent/ES2543795T3/es active Active
- 2011-03-31 HU HUE11714373A patent/HUE026885T2/en unknown
- 2011-03-31 ES ES15158279T patent/ES2757591T3/es active Active
- 2011-03-31 WO PCT/GB2011/000498 patent/WO2011121306A1/en not_active Ceased
- 2011-03-31 DK DK11714373.5T patent/DK2552465T3/en active
- 2011-03-31 EP EP15158279.8A patent/EP2898890B1/en active Active
- 2011-03-31 GB GB1216469.5A patent/GB2499479A/en not_active Withdrawn
- 2011-03-31 CN CN201180018127.0A patent/CN102892424B/zh not_active Expired - Fee Related
- 2011-03-31 JP JP2013501933A patent/JP5960120B2/ja active Active
-
2012
- 2012-09-09 IL IL221858A patent/IL221858A/en active IP Right Grant
-
2019
- 2019-01-02 US US16/237,889 patent/US20190307819A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102892424A (zh) | 2013-01-23 |
| DK2552465T3 (en) | 2015-07-27 |
| US20190307819A1 (en) | 2019-10-10 |
| HUE026885T2 (en) | 2016-08-29 |
| ES2757591T3 (es) | 2020-04-29 |
| WO2011121306A1 (en) | 2011-10-06 |
| JP5960120B2 (ja) | 2016-08-02 |
| ES2543795T3 (es) | 2015-08-21 |
| IL221858A (en) | 2017-04-30 |
| US10206960B2 (en) | 2019-02-19 |
| CA2795013C (en) | 2018-10-16 |
| CA2795013A1 (en) | 2011-10-06 |
| DK2898890T3 (da) | 2019-11-25 |
| EP2898890A1 (en) | 2015-07-29 |
| EP2898890B1 (en) | 2019-08-21 |
| EP2552465A1 (en) | 2013-02-06 |
| US20130129685A1 (en) | 2013-05-23 |
| GB201216469D0 (en) | 2012-10-31 |
| AU2011234269A1 (en) | 2012-10-04 |
| CN102892424B (zh) | 2015-04-01 |
| GB2499479A (en) | 2013-08-21 |
| EP2552465B1 (en) | 2015-04-22 |
| JP2013524782A (ja) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221858A (en) | Stabilization of viral particles | |
| ZA201308706B (en) | Preparation of high-purity gadobutrol | |
| IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
| IL224369B (en) | Combinations of inhibitors for hepatitis c virus | |
| SG10201610753YA (en) | Purification of virus like particles | |
| GB201003274D0 (en) | Methods of connecting | |
| ZA201303752B (en) | Inhibitors of hepatitis c virus | |
| GB201004638D0 (en) | Separation of gases | |
| IL249920A0 (en) | Stabilization of follicle stimulating hormone | |
| EP2538819A4 (en) | STABILIZATION OF OBJECTS | |
| PL2380962T3 (pl) | Cząstka | |
| SI2407155T1 (sl) | Preparati na osnovi inekalcitola | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| TWM386348U (en) | Improved structure of grille | |
| GB201005520D0 (en) | Stabilisation of viral particles | |
| ZA201107291B (en) | Transport of materials | |
| GB201013522D0 (en) | Chemotherapy of viruses | |
| TWM401944U (en) | Improved structure of speaker | |
| TWM386865U (en) | Residue-filtering structure of juice-extractor | |
| TWM390349U (en) | Structure of door-in-door | |
| TWM388315U (en) | Improved structure of hemoclip | |
| TWM400763U (en) | Improved structure of cold-accumulating cravats | |
| TWM389178U (en) | Improved structure of caster | |
| TWM390745U (en) | Structure improvement of tea-making can | |
| GB201001710D0 (en) | Separation of gases |